BLAVIAL
Approved
Jan 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
12
Data completeness
3/8 — Basic
ELSPAR (asparaginase) by Merck & Co. is (recombinant)-rywn is an enzyme that catalyzes the conversion of the amino acid l-asparagine into aspartic acid and ammonia. First approved in 1978.
Drug data last refreshed 26m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ELSPAR (asparaginase) is a recombinant enzyme that depletes plasma L-asparagine, starving leukemic cells that cannot synthesize their own asparagine. Approved in 1978, it is a foundational treatment for acute lymphoblastic leukemia (ALL) and other hematologic malignancies. The drug exploits a metabolic vulnerability in leukemic cells with low asparagine synthetase expression.
LOE Approaching
As a mature, LOE-approaching product, the ELSPAR brand team likely operates in a maintenance/transition mode with modest headcount and focus shifting toward lifecycle extension or managed decline.
Mechanism of Action
(recombinant)-rywn is an enzyme that catalyzes the conversion of the amino acid L-asparagine into aspartic acid and ammonia. The pharmacological effect of RYLAZE is based on the killing of leukemic cells due to depletion of plasma asparagine. Leukemic cells with low expression of asparagine…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (12)
Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
Started May 2026
30 enrolled
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeT Acute Lymphoblastic Leukemia
Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase
Started Sep 2020
42 enrolled
Acute Pancreatitis
Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma
Started Dec 2019
0NK/T Cell Lymphoma
Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older
Started Jan 2016
0Acute Lymphoblastic Leukemia (ALL)Newly Diagnosed Philadelphia Chromosome NegativeAged 60 Years or Older
A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase
Started Oct 2015
512 enrolled
LymphomaAcute Lymphoblastic Leukemia
Worked on ELSPAR at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.